TAS2R14 Antibody

What is TAS2R14 and why is it significant for research?

TAS2R14 (Taste receptor type 2 member 14, also known as Taste receptor family B member 1 or TRB1) is a G-protein-coupled receptor that belongs to the bitter taste receptor family. It is encoded by the TAS2R14 gene in humans and consists of 317 amino acids arranged in 7 transmembrane domains .

The significance of TAS2R14 extends beyond taste perception to several physiological roles:

• It is the most broadly tuned bitter taste receptor, capable of recognizing a remarkably diverse range of chemical compounds with micromolar-range potency

• It is expressed in extra-oral tissues and has been implicated in innate immune responses, male fertility, and cancer

• It mediates nitric oxide-driven endogenous immune responses with potential therapeutic applications for airway infections

• Its agonists are common among approved drugs and traditional Chinese medicines

This receptor's ability to accommodate multiple dissimilar molecules in its orthosteric-binding site makes it particularly interesting for structure-function studies and drug development efforts .

What applications are TAS2R14 antibodies validated for?

Commercial TAS2R14 antibodies have been validated for multiple experimental applications:

The reactivity of these antibodies has been confirmed for human, mouse, and rat samples . When considering applications beyond these species, researchers should perform a sequence homology analysis between the target species and the immunogen sequence used to generate the antibody .

What detection methods can be used with TAS2R14 antibodies?

TAS2R14 antibodies can be paired with various detection systems depending on the experimental requirements:

• Direct detection using conjugated antibodies (fluorophores, enzymes)

• Indirect detection using secondary antibodies

• Signal amplification systems for enhanced sensitivity

Multiple conjugation options are available for custom applications, including:

For specialized applications, custom conjugation services are available from antibody providers .

How should TAS2R14 antibodies be stored and handled?

For optimal performance and longevity of TAS2R14 antibodies, follow these storage and handling recommendations:

• Store at -20°C for long-term storage (up to one year)

• For frequent use and short-term storage (up to one month), store at 4°C

• Avoid repeated freeze-thaw cycles as this can degrade antibody quality

• Store in appropriate buffer conditions (typically PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide)

• When performing buffer exchange for conjugation purposes, use a sodium azide-free buffer like pure PBS

• After reconstitution (if applicable), centrifuge to remove any insoluble material

Small aliquots can be prepared for storage at -20°C to minimize freeze-thaw cycles while maintaining antibody integrity .

How can researchers validate TAS2R14 antibody specificity for their experimental system?

Validating antibody specificity is critical for experimental rigor. For TAS2R14 antibodies, comprehensive validation should include:

• Positive and negative controls:

  • Use tissues/cells known to express TAS2R14 (tongue epithelium, specific immune cells)

  • Include knockout/knockdown samples as negative controls

  • Compare with tissues known to lack TAS2R14 expression

• Peptide blocking experiments:

  • Pre-incubate the antibody with a synthesized peptide corresponding to the immunogen

  • Compare staining patterns with and without peptide blocking (demonstrated effective in the MCF7 cell line)

• Molecular weight verification:

  • TAS2R14 has a calculated molecular weight of 36.16 kDa, but is observed at ~72 kDa in Western blots

  • This discrepancy may be due to post-translational modifications or dimerization

  • Verify using different sample preparation methods to rule out artifacts

• Cross-reactivity assessment:

  • Test reactivity with other TAS2R family members to ensure specificity

  • Sequence alignment analysis between the immunogen and related proteins

Validation should be performed for each new experimental system, tissue type, or species being investigated .

What approaches can be used to study TAS2R14 function in relation to innate immunity?

Recent research has identified TAS2R14 as playing important roles in innate immune responses. The following methodological approaches are recommended:

• Cell-based functional assays:

  • Compare responses in wild-type versus TAS2R14-deficient cells (via CRISPR knockout or siRNA)

  • Measure cytokine/chemokine production using ELISA or multiplexed bead-based assays

  • Assess functional outcomes like antimicrobial peptide secretion, bacterial killing, or phagocytosis

• G-protein coupling analysis:

  • Use NanoBRET assays to study T2R14 interactions with G proteins (particularly Gαi)

  • Assess cAMP levels following TAS2R14 activation in the presence/absence of Gαi inhibitors

  • Compare signaling patterns between normal and disease states (e.g., CF versus non-CF cells)

• Bacterial challenge models:

  • Challenge cells with live bacteria (e.g., P. aeruginosa, S. aureus) and quorum sensing molecule (QSM) deficient strains

  • Compare innate immune marker secretion between wild-type and TAS2R14-deficient cells

  • Assess responses to purified bacterial quorum sensing molecules

Research has shown that TAS2R14-Gαi coupling mediates enhanced immune responses in cystic fibrosis human bronchial epithelial cells, suggesting this receptor as an attractive target for immune modulation .

How can structure-based modeling be applied to develop TAS2R14 agonists?

Despite low sequence similarity to available experimental structures (~10%), structure-based modeling has successfully enabled development of TAS2R14 agonists. The methodology involves:

• Homology modeling and refinement:

  • Generate initial models based on available GPCR crystal structures

  • Refine models using ligand-receptor interaction data

  • Validate models through their ability to discriminate between active and inactive compounds

• Virtual screening workflow:

  • Start with known agonists (e.g., flufenamic acid which activates TAS2R14 at sub-micromolar concentrations)

  • Design analogs using bioisosteric replacement strategies

  • Evaluate binding modes through molecular docking simulations

• Experimental validation and model refinement:

  • Synthesize candidate compounds

  • Determine EC50 values through cell-based assays

  • Use structure-activity relationships to refine the binding site model

This integrated approach has yielded novel TAS2R14 agonists with improved potency compared to lead compounds and provides a framework for structure-based discovery even when high-resolution structures are unavailable .

What methods are available to assess TAS2R14 agonist effects on mast cell degranulation?

TAS2R14 agonists can inhibit mast cell degranulation, suggesting potential therapeutic applications for allergic conditions. To evaluate this effect, researchers can employ:

• β-hexosaminidase release assays:

  • Measure release of β-hexosaminidase (a granule component) as an indicator of degranulation

  • Compare release patterns in the presence of TAS2R14 agonists versus controls

  • Quantify dose-dependent inhibition of IgE-induced degranulation

• Real-time cell analysis (RTCA):

  • Monitor cellular responses in real-time using impedance-based platforms

  • Assess kinetics of mast cell activation and degranulation

  • Evaluate effects of TAS2R14 agonists on temporal response patterns

• Calcium mobilization assays:

  • Use HEK293-TAS2R14-G16gust44 cell line to evaluate agonistic activity

  • Measure calcium flux using fluorescent indicators

  • Determine EC50 values of agonists (e.g., Saikosaponin b shows EC50 of 4.9 μM)

• Molecular docking studies:

  • Model direct binding interactions between agonists and TAS2R14

  • Identify key residues involved in binding (e.g., Saikosaponin b forms H-bond interactions with Arg160, Ser170, and Glu259)

These methodologies have confirmed that specific TAS2R14 agonists like Saikosaponin b from Radix Bupleuri can inhibit IgE-induced mast cell degranulation, presenting a promising approach for allergic asthma treatment .

How can researchers investigate TAS2R14 expression in different tissues and disease states?

To comprehensively characterize TAS2R14 expression patterns across tissues and in disease conditions:

• Transcriptional analysis:

  • Quantitative PCR (qPCR) to measure mRNA expression levels

  • nCounter analysis for parallel quantification of multiple gene targets

  • RNA-seq for genome-wide expression profiling

  • Compare expression between disease (e.g., cystic fibrosis) and non-disease states

• Protein detection:

  • Western blot analysis to quantify protein levels using validated antibodies

  • Immunohistochemistry to localize expression in tissue sections

  • Flow cytometry for single-cell level expression analysis in heterogeneous populations

  • Immunofluorescence with co-localization studies for cellular distribution

• Functional correlations:

  • Correlate expression levels with functional responses to TAS2R14 agonists

  • Assess relationship between expression and disease severity or clinical outcomes

  • Investigate expression changes in response to environmental stimuli or treatments

Studies have identified significantly higher TAS2R14 mRNA expression in cystic fibrosis bronchial epithelial cells compared to non-CF cells, although protein levels were not significantly altered. This highlights the importance of examining both transcriptional and translational regulation in different disease contexts .

How can TAS2R14 antibodies be employed in studying extra-oral bitter taste receptor functions?

TAS2R14 and other bitter taste receptors have been discovered in numerous extra-oral tissues, opening new research directions:

• Respiratory system applications:

  • Immunolocalization of TAS2R14 in airway epithelial cells

  • Investigation of receptor regulation during infection or inflammation

  • Correlation of expression patterns with respiratory disease phenotypes

• Immunological studies:

  • Characterization of TAS2R14 expression in immune cell subsets

  • Analysis of receptor involvement in pathogen recognition

  • Assessment of receptor-mediated modulation of inflammatory responses

• Reproductive biology:

  • Evaluation of TAS2R14 expression in testicular tissues and spermatozoa

  • Investigation of potential roles in male fertility

  • Correlation studies between receptor polymorphisms and reproductive outcomes

• Cancer research:

  • Examination of TAS2R14 expression in different cancer types

  • Analysis of receptor-mediated effects on cancer cell proliferation and survival

  • Exploration of potential therapeutic targeting strategies

For all these applications, researchers should employ multiple complementary techniques (e.g., immunoblotting, immunofluorescence, functional assays) to establish conclusive evidence for receptor expression and function in different cellular contexts.

What considerations are important when translating TAS2R14 research to therapeutic applications?

As TAS2R14 emerges as a potential therapeutic target, several important considerations should guide research translation:

• Target validation requirements:

  • Demonstrate causal relationship between receptor activation and therapeutic effects

  • Validate findings across multiple experimental models and species

  • Establish specificity of effects to TAS2R14 versus other bitter taste receptors

• Agonist development strategies:

  • Design compounds with improved potency (current agonists typically work in micromolar range)

  • Optimize pharmacokinetic properties for target tissue delivery

  • Develop structure-based screening methods to identify novel scaffold classes

• Safety and specificity considerations:

  • Address potential off-target effects due to TAS2R14's broad expression pattern

  • Consider consequences of receptor activation in different tissues

  • Evaluate potential for desensitization with chronic administration

• Disease-specific applications:

  • For respiratory diseases: focus on modulating innate immune responses and antimicrobial activity

  • For allergic conditions: target mast cell degranulation inhibition

  • For cancer: investigate antiproliferative effects in specific tumor types

Higher potency ligands are being developed to investigate TAS2R14 function and modulate it for future clinical applications, with structure-based design approaches showing promise despite the challenges of working with this receptor family .

How can cross-species differences in TAS2R14 be addressed in translational research?

When conducting TAS2R14 research with translational goals, addressing species differences is critical:

• Sequence homology analysis:

  • Compare TAS2R14 sequences across species of interest (human, mouse, rat, non-human primates)

  • Identify conserved domains likely critical for function

  • Map species-specific variations that may affect agonist binding or signaling

• Antibody cross-reactivity verification:

  • Perform BLAST analysis between antibody immunogen sequence and target species sequence

  • Conduct pilot tests with appropriate controls when using antibodies in new species

  • Document cross-reactivity findings to build knowledge base for the research community

• Functional conservation assessment:

  • Compare responses to known TAS2R14 agonists across species

  • Evaluate G-protein coupling profiles in different species

  • Determine if downstream signaling pathways are conserved

• Model system selection:

  • Choose appropriate animal models based on receptor homology and expression patterns

  • Consider developing humanized models for highly divergent systems

  • Validate key findings in human primary cells or tissues when possible